Loading...

Syros Pharmaceuticals

DB:0S9
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0S9
DB
$295M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Syros Pharmaceuticals has significant price volatility in the past 3 months.
0S9 Share Price and Events
7 Day Returns
-1.1%
DB:0S9
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-36.4%
DB:0S9
-7.4%
DE Biotechs
-5.6%
DE Market
0S9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Syros Pharmaceuticals (0S9) -1.1% -22.1% 18.6% -36.4% - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 0S9 underperformed the Biotechs industry which returned -7.4% over the past year.
  • 0S9 underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
0S9
Industry
5yr Volatility vs Market
Related Companies

0S9 Value

 Is Syros Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Syros Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €6.13.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Syros Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Syros Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0S9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.91
NasdaqGS:SYRS Share Price ** NasdaqGS (2019-04-24) in USD $6.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Syros Pharmaceuticals.

DB:0S9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SYRS Share Price ÷ EPS (both in USD)

= 6.96 ÷ -1.91

-3.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syros Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Syros Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Syros Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:0S9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
-2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Syros Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Syros Pharmaceuticals's assets?
Raw Data
DB:0S9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.33
NasdaqGS:SYRS Share Price * NasdaqGS (2019-04-24) in USD $6.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:0S9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SYRS Share Price ÷ Book Value per Share (both in USD)

= 6.96 ÷ 2.33

2.99x

* Primary Listing of Syros Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Syros Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Syros Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Syros Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

0S9 Future Performance

 How is Syros Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Syros Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Syros Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Syros Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Syros Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0S9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0S9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts -2%
DB:0S9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 62%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0S9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0S9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 118 -55 3
2022-12-31 57 -87 3
2021-12-31 7 -105 3
2020-12-31 1 -92 5
2019-12-31 2 -78 7
DB:0S9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -40 -62
2018-09-30 1 -37 -60
2018-06-30 1 -37 -58
2018-03-31 0 -34 -57
2017-12-31 1 -45 -54
2017-09-30 1 -44 -50
2017-06-30 1 -43 -50
2017-03-31 1 -43 -51
2016-12-31 0 -41 -51
2016-09-30 0 -39 -52
2016-06-30 0 -35 -48
2016-03-31 0 -30 -41

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Syros Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Syros Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0S9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Syros Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0S9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.81 0.35 -1.48 3.00
2022-12-31 -1.37 -0.75 -1.77 3.00
2021-12-31 -1.96 -1.54 -2.50 3.00
2020-12-31 -2.06 -1.84 -2.41 5.00
2019-12-31 -2.09 -1.75 -2.30 7.00
DB:0S9 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.91
2018-09-30 -1.93
2018-06-30 -1.99
2018-03-31 -2.10
2017-12-31 -2.13
2017-09-30 -2.01
2017-06-30 -2.11
2017-03-31 -2.82
2016-12-31 -4.05
2016-09-30 -7.07
2016-06-30 -20.30
2016-03-31 -19.13

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Syros Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Syros Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Syros Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

0S9 Past Performance

  How has Syros Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Syros Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Syros Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Syros Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Syros Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Syros Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Syros Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0S9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.05 -62.28 16.16 50.18
2018-09-30 1.16 -59.55 15.53 46.83
2018-06-30 0.75 -57.64 15.25 44.43
2018-03-31 0.37 -56.96 14.88 43.38
2017-12-31 1.10 -54.01 13.89 41.90
2017-09-30 1.42 -49.67 13.07 38.56
2017-06-30 1.42 -50.14 12.11 39.70
2017-03-31 1.42 -50.61 11.18 39.18
2016-12-31 0.32 -51.42 10.46 37.82
2016-09-30 0.00 -52.39 9.86 37.75
2016-06-30 0.00 -47.81 8.82 33.03
2016-03-31 0.32 -41.29 7.26 28.94
2015-12-31 0.32 -34.75 5.73 24.41
2015-09-30 0.32 -27.65 4.09 19.05
2014-12-31 -15.64 2.51 10.92
2013-12-31 -9.26 2.37 6.27

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Syros Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Syros Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Syros Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Syros Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Syros Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

0S9 Health

 How is Syros Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Syros Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Syros Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Syros Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Syros Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3281.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Syros Pharmaceuticals Company Filings, last reported 3 months ago.

DB:0S9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 78.59 0.03 99.68
2018-09-30 94.84 0.03 113.23
2018-06-30 108.71 0.04 124.37
2018-03-31 104.50 0.01 121.74
2017-12-31 65.32 0.05 72.05
2017-09-30 78.59 0.10 81.95
2017-06-30 91.08 0.14 91.52
2017-03-31 70.14 0.18 70.49
2016-12-31 80.60 0.22 83.59
2016-09-30 90.78 0.26 93.49
2016-06-30 53.39 0.30 50.12
2016-03-31 63.92 0.32 62.13
2015-12-31 34.05 0.34 35.91
2015-09-30 43.83 0.36 44.99
2014-12-31 60.24 0.00 60.39
2013-12-31 3.97 0.00 3.80
  • Syros Pharmaceuticals's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Syros Pharmaceuticals has sufficient cash runway for 2.4 years based on current free cash flow.
  • Syros Pharmaceuticals has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 6.3% each year.
X
Financial health checks
We assess Syros Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Syros Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

0S9 Dividends

 What is Syros Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Syros Pharmaceuticals dividends.
If you bought €2,000 of Syros Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Syros Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Syros Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0S9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0S9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Syros Pharmaceuticals has not reported any payouts.
  • Unable to verify if Syros Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Syros Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Syros Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Syros Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Syros Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Syros Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

0S9 Management

 What is the CEO of Syros Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nancy Simonian
COMPENSATION $2,223,397
AGE 57
TENURE AS CEO 6.8 years
CEO Bio

Dr. Nancy A. Simonian, M.D., has been the Chief Executive Officer and President at Syros Pharmaceuticals, Inc. since July 2012. Dr. Simonian has served as a Director of Evelo Biosciences, Inc. Since April 2018. Dr. Simonian served as the Principal Financial Officer of Syros Pharmaceuticals, Inc. since September 28, 2017 until December 06, 2017. She served as the Chief Medical Officer of Clinical, Medical & Regulatory Affairs at Millennium Pharmaceuticals, Inc. She served as the Chief Medical Officer of Millennium Pharmaceuticals Inc. since 2006. While at Millennium, Dr. Simonian has built a strong clinical development organization which effectively executes on a diverse pipeline of product candidates in Millennium Pharmaceuticals Inc.'s oncology, inflammatory disease and cardiovascular disease focus areas. She served as Senior Vice President, Clinical, Regulatory and Medical Affairs of Millennium Pharmaceuticals Inc. from March 14, 2005 to 2006. She was responsible for guiding the clinical development process for the approval of VELCADE. In her expanded role, Dr. Simonian leads an integrated medical organization which consolidates all medical functions, including clinical development, regulatory affairs, pharmacovigilance and global medical affairs. She joined Millennium Pharmaceuticals in 2001. She co-leads Millennium Pharmaceuticals Inc.’s pipeline portfolio review committee and direct a streamlined clinical drug development process through post-approval life- cycle. Dr. Simonian served at Biogen, Inc. from 1995 to 2001 and also held the positions of Vice President of Medical Research/clinical research. At Biogen, she was responsible for the oversight of Avonex Tysabri, as well as multiple gene therapy clinical development programs. She successfully filed sNDAS for Avonex and led the in-licensing of Tysabri from Elan Pharmaceuticals. She has been a Director of Seattle Genetics, Inc. since March 2012 and Syros Pharmaceuticals, Inc since April 2013. Dr. Simonian served as a Director of Arqule Inc. from May 12, 2006 to March 31, 2011. Dr. Simonian is Assistant Clinical Professor, Neurology, at Harvard Medical School/Massachusetts General Hospital. Dr. Simonian holds a BA in Biology from Princeton University in 1983 and an M.D. from the University Of Pennsylvania Medical School in 1988. Dr. Simonian completed her internship in Medicine and residency in Neurology at Harvard Medical School/Massachusetts General Hospital.

CEO Compensation
  • Nancy's compensation has increased whilst company is loss making.
  • Nancy's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Syros Pharmaceuticals management team in years:

3
Average Tenure
56
Average Age
  • The tenure for the Syros Pharmaceuticals management team is about average.
Management Team

Nancy Simonian

TITLE
President
COMPENSATION
$2M
AGE
57
TENURE
6.8 yrs

Rick Young

TITLE
Scientific Founder
COMPENSATION
$152K
AGE
64

David Roth

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
55
TENURE
3.3 yrs

Jeremy Springhorn

TITLE
Chief Business Officer
COMPENSATION
$2M
AGE
56
TENURE
1.4 yrs

Nathanael Gray

TITLE
Scientific Founder & Member of Scientific Advisory Board

Joe Ferra

TITLE
Chief Financial Officer
AGE
42
TENURE
1.1 yrs

Eric Olson

TITLE
Chief Scientific Officer
AGE
60
TENURE
6 yrs

Gerald Quirk

TITLE
Chief Legal & Administrative Officer and Secretary
COMPENSATION
$1M
AGE
50
TENURE
2.6 yrs

Naomi Aoki

TITLE
Vice President of Corporate Communications & Investor Relations

Christian Fritz

TITLE
Head of Biology
Board of Directors Tenure

Average tenure and age of the Syros Pharmaceuticals board of directors in years:

6
Average Tenure
64
Average Age
  • The tenure for the Syros Pharmaceuticals board of directors is about average.
Board of Directors

Peter Wirth

TITLE
Chairman
COMPENSATION
$238K
AGE
68
TENURE
2.3 yrs

Nancy Simonian

TITLE
President
COMPENSATION
$2M
AGE
57
TENURE
6 yrs

Rick Young

TITLE
Scientific Founder
COMPENSATION
$152K
AGE
64
TENURE
6 yrs

Nathanael Gray

TITLE
Scientific Founder & Member of Scientific Advisory Board
TENURE
6 yrs

Marsha Fanucci

TITLE
Director
COMPENSATION
$167K
AGE
64
TENURE
3.5 yrs

Amir Nashat

TITLE
Director
COMPENSATION
$165K
AGE
45
TENURE
3.3 yrs

Phil Sharp

TITLE
Member of Scientific Advisory Board & Director
COMPENSATION
$159K
AGE
73
TENURE
6.3 yrs

Bradley Bernstein

TITLE
Member of Scientific Advisory Board

Scott Biller

TITLE
Member of Scientific Advisory Board
AGE
62
TENURE
6 yrs

Gerard Evan

TITLE
Member of Scientific Advisory Board
TENURE
6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Apr 19 Buy Samsara BioCapital LLC Company 09. Apr 19 09. Apr 19 533,332 €6.65 €3,549,191
14. Mar 19 Sell Arch Venture Partners, L.P. Company 12. Mar 19 14. Mar 19 -167,503 €7.25 €-1,161,194
11. Mar 19 Sell Arch Venture Partners, L.P. Company 07. Mar 19 11. Mar 19 -164,583 €6.17 €-996,045
X
Management checks
We assess Syros Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Syros Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

0S9 News

Simply Wall St News

0S9 Company Info

Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Details
Name: Syros Pharmaceuticals, Inc.
0S9
Exchange: DB
Founded: 2011
$263,881,868
42,433,197
Website: http://www.syros.com
Address: Syros Pharmaceuticals, Inc.
620 Memorial Drive,
Suite 300,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SYRS Common Stock Nasdaq Global Select US USD 30. Jun 2016
DB 0S9 Common Stock Deutsche Boerse AG DE EUR 30. Jun 2016
LSE 0LC7 Common Stock London Stock Exchange GB USD 30. Jun 2016
Number of employees
Current staff
Staff numbers
76
Syros Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:05
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.